Drug Database
DO

doxorubicin (doxorubicin, Nanox / Doxonax)

✓ Approved

Nanox · TOP2A · 小分子

什么是 doxorubicin?

doxorubicin 是一种小分子,由Nanox研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名doxorubicin, Nanox, Doxonax
公司Nanox
药物类别小分子
分子靶点TOP2A
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

doxorubicin 作用于 1 个分子靶点:

TOP2ADNA topoisomerase II alpha (TOP2alpha, TOPIIA)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

doxorubicin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved

相关研究文献

PubMedHaematologica2026-11-19

Preserving liposomal anthracycline exposure and reconsidering radiotherapy in frontline therapy of older adults with advanced-stage classical Hodgkin lymphoma. Comment on: "Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?"

Giordano Claudia C, Picardi Marco M

PMID 43053699
阅读全文 →
PubMedJournal of translational medicine2026-11-19

In vitro biological evaluation of a water-soluble hyperbranched β-cyclodextrin nanocarrier for co-delivery of doxorubicin and curcumin.

Samadzadeh Meisam M, Salmanifard Ardestani Mohammad Taha MT, Zarepour Atefeh A, Khosravi Arezoo A et al.

Conventional chemotherapy is often limited by poor aqueous solubility, systemic toxicity, and low bioavailability. To address these limitations, a water-dispersible hyperbranched β-cyclodextrin (HBCD) crosslinked with 1,2,3,4-butanetetracarboxylic acid (BTCA) was developed as a nanocarrier for the co-delivery of doxorubicin (DOX) and curcumin (CUR). HBCD was synthesized under optimized conditions and characterized using complementary physicochemical techniques. DOX and CUR were loaded individually and in combination, and drug release kinetics were evaluated. Biological performance was assessed by hemolysis, cytocompatibility, cellular uptake assessment, apoptosis analyses, anticancer activity, and concentration-dependent drug interaction analysis using SynergyFinder+. The optimized HBCD exhibited favorable physicochemical properties and excellent water solubility. Encapsulation efficiencies in the co-loaded formulation reached 50.8% for DOX and 45.7% for CUR. Drug release showed an initial burst followed by sustained release over 96 h, with kinetics best described by the Korsmeyer-Peppas model. HBCD demonstrated excellent hemocompatibility (<2% hemolysis) and high cytocompatibility toward HDF cells. Drug-loaded formulations produced concentration-dependent cytotoxicity in cancer cell lines. Cellular association and apoptosis analyses confirmed the biological activity of the formulations, while SynergyFinder+ indicated predominantly additive drug interactions with localized concentration-dependent positive interaction regions rather than uniform synergism. BTCA-crosslinked water-dispersible HBCD provides an effective platform for the co-delivery of hydrophilic and hydrophobic anticancer agents, combining efficient drug loading, sustained release, hemocompatibility, and encouraging in vitro biological performance. These findings establish a foundation for future mechanistic, pharmacokinetic, and in vivo studies to further evaluate the translational potential of this delivery system.

PMID 43053162
阅读全文 →
PubMedCardio-oncology (London, England)2026-11-19

Assessment of the HFA-ICOS risk tool for predicting cancer therapy-related cardiac dysfunction: a prospective cohort study.

Guerra Enrique C EC, Aparicio-Ortiz Alexis D AD, Barac Ana A, Asch Federico M FM et al.

Anthracyclines and HER2-targeted breast cancer treatments can cause cancer therapy-related cardiac dysfunction (CTRCD). The Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) risk tool assesses this risk, but its accuracy remains uncertain. We aimed to (1) determine CTRCD incidence using the 2021 CTRCD definition in breast-cancer patients receiving doxorubicin and/or trastuzumab; (2) evaluate the HFA-ICOS risk proformas, and (3) assess the individual risk factors incorporated in the proformas. In this prospective study, 186 women with early-stage breast cancer were enrolled to undergo baseline and serial cardiac evaluations over 12 months. After exclusions, 177 patients were included for risk stratification using the Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) score. Baseline risk distribution was 67% low (n = 116), 28% moderate (n = 52), and 5% high (n = 9). During follow-up, 53 patients (28.6%) developed cancer therapy-related cardiac dysfunction (CTRCD), corresponding to an overall incidence rate of 0.266 events per person-year (95% CI 0.200-0.348). Incidence rates were 0.326, 0.145, and 0.248 in the low-, moderate-, and high-risk groups, respectively; pairwise 365-day restricted mean survival time (RMST) comparisons did not remain statistically significant after Holm adjustment (all adjusted p > = 0.124). In Cox models adjusted for treatment type, CTRCD risk did not differ significantly between the moderate- and high-risk groups compared with the low-risk group. The ordinal HFA-ICOS category showed poor discrimination for time to CTRCD (Harrell C-index 0.43, 95% CI 0.37-0.49). The HFA-ICOS proforma showed limited ability to stratify CTRCD risk in this cohort. These findings highlight limitations in current guideline-based risk models and the need for improved stratification strategies.

PMID 43053233
阅读全文 →
PubMedCell death discovery2026-11-18

The Drp1 inhibitor DRP1i2 confers cardioprotection against doxorubicin-induced cardiotoxicity.

Deng Yali Y, Bass-Stringer Sebastian S, Bond Simon T ST, Cross Jonathon J et al.

Anthracyclines such as doxorubicin are highly effective chemotherapeutic agents, but their clinical use is limited by dose-dependent cardiotoxicity associated with mitochondrial dysfunction. Dysregulated mitochondrial dynamics, particularly excessive dynamin-related protein 1 (Drp1)-mediated fission, has been implicated in cardiac injury. We investigated whether DRP1i2, a novel small-molecule Drp1 inhibitor targeting a conserved domain, mitigates doxorubicin-induced cardiotoxicity while preserving anticancer efficacy. Cardioprotective effects were assessed in a murine model of chronic doxorubicin cardiotoxicity and in human induced pluripotent stem cell-derived cardiac microtissues, while anticancer activity was evaluated across multiple cancer cell lines in 2D and 3D systems. DRP1i2 preserved left ventricular systolic function in vivo, reduced interstitial fibrosis and cardiomyocyte atrophy, and attenuated myocardial proteomic remodelling. In human cardiac microtissues, DRP1i2 improved viability and restored contractile function despite persistent mitochondrial oxidative stress and metabolic dysfunction. In cancer models, DRP1i2 did not compromise doxorubicin efficacy across A549 lung cancer, OVCAR3 ovarian cancer, and MDA-MB-231 breast cancer cell lines, and exhibited modest anticancer activity in MG63 osteosarcoma cells. These findings demonstrate that DRP1i2 confers cardioprotection while maintaining anticancer efficacy via modulation of Drp1-dependent mitochondrial dynamics, supporting mitochondrial fission as a targetable pathway to mitigate doxorubicin-induced cardiotoxicity.

PMID 43045685
阅读全文 →
PubMedJournal of cellular and molecular medicine2026-11-18

Drug-Carrier Interactions in PEGylated Liposomal Doxorubicin-Associated Renal Toxicity: A Systems-Level Analysis of Complement-Coagulation Crosstalk.

Ye Huirong H, Qin Youfa Y, Chen Liping L, Ouyang Suidong S et al.

PEGylated liposomal doxorubicin (PLD) is widely used in cancer therapy, yet rare cases of renal-limited thrombotic microangiopathy (TMA) have been reported, characterized by glomerular endothelial injury and microvascular thrombosis. The mechanisms underlying this distinct nephrotoxicity remain poorly understood, particularly the potential contribution of drug-carrier interactions. Here, we developed an integrated multi-layer network toxicology framework to systematically investigate PLD-associated renal injury. By integrating doxorubicin-associated targets, carrier-associated complement pathways, nephrotoxicity-associated genes and renal injury-responsive transcriptomic signatures, we identified 98 computationally derived candidate genes and constructed a mechanistic interaction network. Enrichment analyses highlighted complement activation and complement-coagulation crosstalk, while transcriptomic data indicated endothelial dysfunction, inflammatory activation and oxidative stress. PTGS2 and SERPINE1 were prioritized as candidate molecular convergence nodes linking inflammatory and prothrombotic signalling, and molecular docking and dynamics analyses supported in silico interactions between doxorubicin and these proteins. Immune-related transcriptional signature analyses further indicated enrichment of gene programs associated with macrophage, neutrophil and dendritic-cell signatures in renal injury. These findings suggest a candidate dual-hit model in which doxorubicin-induced intracellular stress and carrier-associated complement activation may converge toward endothelial injury as well as inflammation-coagulation crosstalk, potentially contributing to PLD-associated renal TMA.

PMID 43049223
阅读全文 →
PubMedLuminescence : the journal of biological and chemical luminescence2026-11-18

Complexation-Induced Ring Opening of a Rhodamine 6G-Pyridoxal Schiff Base Probe for Cascade Fluorescence Sensing of Fe3+ and Doxorubicin in Aqueous Media.

Bhardwaj Kanishk K, Jangir Ritambhara R, Jali Bigyan R BR, Sahoo Suban K SK

A rhodamine 6G-pyridoxal Schiff base probe RPY was synthesized and characterized by various analytical techniques. Schiff base RPY exhibited a distinct fluorescence turn-on response at 557 nm toward Fe3+ with a detection limit of 1.04 nM. The sensing response is attributed to complexation-induced opening of the rhodamine spirolactam ring, which restores the conjugated xanthene fluorophore. Job's plot analysis indicated a 1:1 complex formation between RPY and Fe3+, and the fluorescence lifetime studies further supported the formation of a fluorescent RPY-Fe3+ complex. Real-sample recovery studies showed satisfactory recoveries of Fe3+, demonstrating the analytical applicability of RPY for Fe3+ detection. Furthermore, the in situ formed RPY-Fe3+ complex was used as a cascade platform for fluorescent turn-off sensing of doxorubicin.

PMID 43046339
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多doxorubicin